Idarubicin overcomes P-glycoprotein-related multidrug resistance: comparison with doxorubicin and daunorubicin in human multiple myeloma cell lines
- 10 May 1999
- journal article
- research article
- Published by Elsevier in Leukemia Research
- Vol. 23 (6) , 539-548
- https://doi.org/10.1016/s0145-2126(99)00041-7
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Lung-Resistance–Related Protein Expression Is a Negative Predictive Factor for Response to Conventional Low but not to Intensified Dose Alkylating Chemotherapy in Multiple MyelomaBlood, 1998
- Upregulated expression of BCL-2 in multiple myeloma cells induced by exposure to doxorubicin, etoposide, and hydrogen peroxideBlood, 1996
- The drug resistance-related protein LRP is the human major vault proteinNature Medicine, 1995
- Overexpression of a Transporter Gene in a Multidrug-Resistant Human Lung Cancer Cell LineScience, 1992
- Modulation of multidrug-resistant multiple myeloma by cyclosporinThe Lancet, 1992
- Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cellsBlood, 1992
- Expression of the bcl-2 gene in human multiple myeloma cell lines and normal plasma cellsBlood, 1992
- A rapid and sensitive flow cytometric method for the detection of multidrug‐resistant cellsCytometry, 1989
- Immunohistochemical detection and quantitation of P-glycoprotein in multiple drug-resistant human myeloma cells: association with level of drug resistance and drug accumulationBlood, 1989
- Effective Treatment of Advanced Multiple Myeloma Refractory to Alkylating AgentsNew England Journal of Medicine, 1984